Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery

被引：12

作者：

Kavuncu S. ^{[1
,2
]}

Horoz H. ^{[3
]}

Ardagil A. ^{[3
]}

Erbil H.H. ^{[3
]}

机构：

[1] Ankara Ulucanlar Eye Hospital, Ankara

[2] Ankara 06450

[3] Department of Ophthalmology, Goztepe Research and Education Hospital, Istanbul

来源：

International Ophthalmology | 2008年 / 28卷 / 4期

关键词：

Cataract surgery; Early postoperative inflammation; Prednisolone acetate; Rimexolone;

D O I：

10.1007/s10792-007-9131-0

中图分类号：

学科分类号：

摘要：

Purpose: To compare the efficacy and safety of rimexolone 1% and prednisolone acetate 1% ophthalmic suspensions in controlling intraocular inflammation in the early period after cataract surgery. Methods: Eighty patients undergoing cataract extraction with intraocular lens implantation, either planned extra capsular cataract extraction (PECCE) or phacoemulsification surgery, were evaluated in a prospective, randomized, observer-masked, clinical trial in which efficacy in controlling early postoperative inflammation and safety of prednisolone acetate 1% one eye drop every 4 h (n = 36 eyes) was compared with that of rimexolone 1% one eye drop every 4 h (n = 44 eyes) in an eighteen day course. Efficacy was assessed from changes of the anterior chamber cell count, flare, conjunctival hyperemia, and ciliary congestion by means of slit lamp biomicroscopy on days 1, 3, 8, 15, and 18. Intraocular pressure (IOP) and possible side effects were also recorded on each visit. Results: Anterior chamber cell count and flare showed no difference in the two groups at any visits. The rimexolone group was associated with significantly higher score for conjunctival hyperemia on days one and three (P < 0.05) and the prednisolone acetate group was associated with a significantly higher score for corneal edema on day 8 (P < 0.05). However, there were no between group differences in IOP. Conclusions: Rimexolone 1% ophthalmic suspension was as effective and safe as prednisolone acetate 1% ophthalmic suspension in controlling inflammation in the early period after cataract surgery. © Springer Science+Business Media B.V. 2007.

引用

页码：281 / 285

页数：4

共 16 条

[1]

Leibowitz H.M., Kupferman A., Bioavailability and therapeutic effectiveness of topically administered corticosteroids, Trans Am Acad Ophthalmol Otolaryngol, 79, pp. 78-88, (1975)

[2]

Simone J.N., Whitecare M.M., Effects of anti-inflammatory drugs following cataract extraction, Curr Opinion Ophthalmol, 12, pp. 63-67, (2001)

[3]

Leibowitz H.M., Bartlett J.D., Rich R., McQuirter H., Steward R., Assil K., Intraocular pressure-raising potential of 1% rimexolone in patients responding to corticosteroids, Arch Ophthalmol, 116, pp. 933-937, (1996)

[4]

Rowen S., Preoperative and postoperative medications used for cataract surgery, Curr Opin Ophthalmol, 10, pp. 29-35, (1999)

[5]

Assil K.K., Massry G., Lehnmann R., Fox K., Stewart R., Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension, J Cataract Refract Surg, 23, pp. 750-757, (1997)

[6]

Bron A., Hoang Xuan T.C., Boureaux Andrieux C., Crozafon B., Hachet E., Medhorn E., Et al., The effects of rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study, Eur J Ophthalmol, 8, pp. 16-21, (1996)

[7]

Foster S., Alter G., DeBarge R., Raizman M., Crabb J., Santos C., Et al., Efficacy and safety of rimexolone 1% ophthalmic suspension vs prednisolone acetate 1% in the treatment of uveitis, Am J Ophthalmol, 122, pp. 171-182, (1996)

[8]

Stark W.J., Whithney C.E., Chandler J.W., Worthern D.M., Trends in intraocular lens implantation in the United States, Arch Ophthalmol, 104, pp. 1769-1770, (1986)

[9]

Lehnmann R., Assil K., Stewart R., Fox K., Comparison of rimexolone 1% ophthalmic suspension to placebo in control of postcataract surgery inflammation, Invest Ophthalmol Vis Sci, 36, SUPPL., (1995)

[10]

Armaly M.F., Effects of corticosteroids on intraocular pressure and fluid dynamics 1. The effects of the dexametasone in the normal eye, Arch Ophthalmol, 70, pp. 482-491, (1963)

← 1 2 →